IDH1 and acute myeloid leukemia: Other mutation-based therapies, specifically ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor), are the first FDA-approved drugs that target metabolism in AML patients, as they induce durable remissions by reducing the levels of the oncometabolite 2-HG [111,112], which leads to a differentiation blockade of AML cells [113].